<DOC>
	<DOCNO>NCT02237768</DOCNO>
	<brief_summary>The purpose study assess bioequivalence investigational TEST product market REFERENCE product measurement Plasma concentration Erythromycylamine calculation bioequivalence parameter measurement follow ANOVA 90 % confidence interval statistical evaluation .</brief_summary>
	<brief_title>Semi-replicate Crossover Bioequivalence Study Dirithromycin ( Abdi İbrahim İlaç San . Ve Tic . A. Ş. , Turkey ) Healthy Subjects Under Fasting Conditions</brief_title>
	<detailed_description>An open-label , randomize , three -period , two-treatment , three -sequence , semi-replicate crossover bioequivalence study washout period least 14 day dos . Healthy , mixed skin Arab &amp; Mediterranean Subjects age 18 50 year , body-mass index 18.5 30.0 kg/m2 inclusive ( minimum 50 kg weight ) , non-smokers light smoker ( smoker 10 cigarette per day ) .</detailed_description>
	<mesh_term>Dirithromycin</mesh_term>
	<mesh_term>Erythromycin</mesh_term>
	<criteria>1 . Healthy subject . 2 . Ethnic Group : Arab &amp; Mediterranean . 3 . Race : Mixed skin ( white &amp; black skin people ) . 4 . Age 1850 year . 5 . Bodymass index 18.5 30.0 kg/m2 inclusive . ( minimum 50 kg weight ) 6 . Subject available whole study period give write informed consent . 7 . Normal Physical examination . 8 . Vital sign within normal range . 9 . All laboratory screening result within normal range , assess clinically Nonsignificant attend physician . 10 . Normal Kidney &amp; Liver function test 1 . Women childbearing potential n't use contraceptive method , pregnant and/or lactate woman . 2 . Ethnic Group ( Non Arab &amp; / Non Mediterranean ) 3 . History severe allergy allergic reaction study drug relate drug heparin 4 . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug 5 . History serious illness impact fate drug 6 . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease . 7 . Clinically significant illness 4 week study Period I 8 . Mental disease . 9 . Smoking 10 cigarette per day 10 . The intake alcohol grapefruit study . 11 . The intake caffeine , xanthenes , CO2containing beverage hospitalization . 12 . Regular use medication . 13 . Having take medication could affect investigated drug product : ) Regular consumption drug two week prior study initiation day , b ) consumption enzyme stimulate inhibit drug ( e.g . Barbiturates , Carbamazepine , Phenytoin , Amphetamine , Benzodiazepine , cannabinoid , cocaine , opiates , phencyclidine methadone ) one month study initiation . 14 . Presence significant physical organ abnormality 15 . Donation 1 ) least 400 ml blood within 60 day , 2 ) 150 ml blood within 30 day , 3 ) 100 ml blood plasma platelet within 14 day study Period I 16 . Participation another bioequivalence study and/or Clinical trial within 80 day prior start study Period I 17 . Following special diet ( e.g . vegetarian ) diet one month study initiation . 18 . Prior history hypersensitivity dirithromycin , erythromycin , macrolide antibiotic 19 . Subjects seizures prior history seizures 20 . Any significant clinical abnormality include HBsAg , HCV , / HIV . 21 . Consumption grapefruit grapefruit containing product within 7 day drug administration 22 . Ingestion vitamins herbal product within 7 day prior initial dose study medication . 23 . Exhausting physical exercise last 48 hour ( e.g . weight lift ) recent significant change dietary exercise habit . 24 . History Liver disease . 25 . Abnormal Vital Signs . 26 . Abnormal Kidney and/or Liver function test . 27 . Vomiting , Diarrhea admission</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Fasting condition</keyword>
</DOC>